NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
2010 Pharmaceuticals Research Review
http://www.reportlinker.com/p0341171/2010-Pharmaceuticals-Research-Review.html
FOREWORD
The economic slowdown has accentuated the fault lines already dividing the pharmaceutical world. Lack of innovation from the large pharma companies, coupled with the patent expiration precipice, has fueled merger and acquisition activity. The in-licensing deals that mirror this trend have been a positive boon for biotech companies with either promising compounds in their pipeline, or promising platforms – most especially for delivering RANi drugs, or uncovering pathways previously held within the domain of academia only.
As a shadow looming behind this field there have also been dramatic change to U.S. health policy through legislation, and the awakening of the increasingly alluring emerging markets in China and India – still small in comparison - but future engines for high growth.
BCC Research has provided comprehensive coverage of pharmaceutical markets for many years, and we are now increasing our production of these research reports. This review of pharmaceutical market research conducted in 2010 is meant to provide a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC was founded in 1971.
This review includes highlights from the following reports on pharmaceutical markets published BCC Research:
Ophthalmic Therapeutic Drugs: Technologies and Global Markets
Global Markets for Orphan Drugs
Drug-Device Combinations: The Global Market
Cardiovascular Therapeutic Drugs: Technologies and Global Markets
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
Antipsychotic Drugs: Technologies and Global Markets
Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets
Oncology Adjuvants: Technologies and Global Markets
The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession. The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.
The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%. The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.
Chapter-1: FOREWORD
FOREWORD 1
Chapter-2: OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM031C):
INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 3
INTENDED AUDIENCE 4
INFORMATION SOURCES 5
RELATED BCC REPORTS 5
BCC ONLINE SERVICES 6
DISCLAIMER 6
SUMMARY 6
TABLE 1 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 ($ MILLIONS) 7
FIGURE 1 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, 2008-2014 ($ MILLIONS) 8
OVERVIEW 9
HISTORY AND CURRENT STATE OF OPHTHALMOLOGY DISEASE 9
Established Drug Classes in Ophthalmology 10
Emerging Drug Classes 10
VEGF-Trap Eye 10
Combination Therapies 11
Competition between VEGF Inhibitors in Wet AMD 11
TABLE 2 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN: PREVIOUS AND EXPECTED 12
Expected Outcome of CATT trial: Avastin v. Lucentis 12
Genetic Specifications of Ophthalmic Disease 13
TABLE 3 SUMMARY OF KNOWN GENES INFLUENCING DISEASE 14
Summary Pipeline of Drugs in Development 14
TABLE 4 RECENTLY APPROVED DRUGS, 2009 15
TABLE 5 SUMMARY PIPELINE FORECAST, 2012-2014 15
INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS 15
INDUSTRY STRUCTURE 15
Market Concentration and Price Sensitivity 16
TABLE 6 COMPANY BY DISEASE CLASS, 2009 REVENUE ($ MILLIONS) 17
Competitive Factors 17
TABLE 7 LARGE REVENUE, BRANDED DRUG SALES COMING OFF PATENT, 2009 18
Chapter-3: GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038C)
INTRODUCTION 19
STUDY GOAL AND OBJECTIVES 19
REASONS FOR DOING THE STUDY 20
INTENDED AUDIENCE 20
SCOPE OF REPORT 21
INFORMATION SOURCES AND METHODOLOGY 21
AUTHOR'S CREDENTIALS 22
RELATED REPORTS FROM BCC RESEARCH 22
SUMMARY 23
TABLE 8 GLOBAL ORPHAN DRUGS DEMAND BY VALUE, THROUGH 2014 ($ MILLIONS) 24
FIGURE 2 GLOBAL ORPHAN DRUGS DEMAND BY VALUE, 2008-2014 ($ MILLIONS) 25
OVERVIEW 25
DEFINITION OF AN ORPHAN DRUG 25
HISTORY OF ORPHAN DRUG LEGISLATION 26
First Legislation on Orphan Drugs 26
Amendments to the ODA 26
Bills Passed in 2002 Increased Funding and Established the Office of Rare Diseases 26
Orphan Drug Legislation — Global Status 26
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT 27
THE NEED FOR INCENTIVES 27
TABLE 9 NUMBER OF ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR BY U.S. FDA, 1983-2009 27
APPLICATIONS FOR ORPHAN DRUG DESIGNATIONS HAVE DOUBLED 28
PROFITABILITY OF ORPHAN DRUGS 28
Market Exclusivity 28
No Regulatory Restrictions on Pricing 29
Off-Label Use 29
CHALLENGES FOR EFFECTIVE USE OF THE ODA 30
MARKET EXCLUSIVITY VERSUS PATENT PROTECTION 30
MARKET SIZE AND KEY PLAYERS 31
TABLE 10 TOP 10 COMPANIES IN THE ORPHAN DRUG MARKET AND THEIR MARKET SHARES (%) 32
THE ORPHAN DRUG ACT — A BONUS FOR BIOTECH 32
BIG PHARMA IS ENTERING THE ORPHAN DRUGS SECTOR AGGRESSIVELY 32
CONCERNS ABOUT THE ORPHAN DRUG ACT 33
COST-EFFECTIVENESS 34
PRICING OF ORPHAN DRUGS 34
TABLE 11 SOME EXAMPLES OF HIGHLY EXPENSIVE ORPHAN DRUGS AND THEIR PRICES 35
High-Priced Orphan Drugs Leading to Price Control Measures by Governments 36
TABLE 12 SOME OF THE RECENT CONTROVERSIES RELATED TO ORPHAN DRUGS PRICING 37
ACCESS TO ORPHAN DRUGS AND REIMBURSEMENT — CURRENT PRACTICES 38
Orphan Drug Access and Reimbursement Scenario in the U.S. 38
Access and Reimbursement Scenario in Europe 38
TABLE 13 ORPHAN DRUG ACCESS AND REIMBURSEMENT PRACTICES IN EUROPEAN COUNTRIES 39
TABLE 13 (CONTINUED) 40
TABLE 13 (CONTINUED) 41
Call for Unification of Orphan Drug Access Across Europe 41
INNOVATIVE APPROACHES OF PRICING AND REIMBURSEMENT 42
TABLE 14 EMERGING TRENDS IN PRICING AND REIMBURSEMENT OF HIGH-PRICED DRUGS 42
TABLE 14 (CONTINUED) 43
Chapter-4: DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET (PHM045B)
INTRODUCTION 44
STUDY GOALS AND OBJECTIVES 44
REASONS FOR DOING THIS STUDY AND ITS IMPORTANCE 44
INTENDED AUDIENCE 45
SCOPE OF REPORT 45
METHODOLOGY AND INFORMATION SOURCES 45
ANALYST CREDENTIALS 46
SUMMARY 46
SCOPE OF THE INDUSTRY 46
DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET 47
TECHNOLOGY AND PATENT ACTIVITY 48
THE CENTRAL ROLE OF THE FDA 48
TABLE 15 SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2014 ($ BILLIONS) 49
FIGURE 3 SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2008-2014 ($ BILLIONS) 49
CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY 50
OVERVIEW 50
ROLE OF THE FDA 50
TABLE 16 RECENT EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS 51
TABLE 16 (CONTINUED) 52
OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL STRUCTURE 52
HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE 52
EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS 53
FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS 54
TABLE 17 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS 55
THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS 55
FDA TRENDS IN REVIEWING COMBINATION PRODUCTS 55
FIGURE 4 COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2007 (NUMBER OF SUBMISSIONS) 56
TABLE 18 FDA COMBINATION PRODUCT CATEGORIES, FY 2004 57
TABLE 19 FDA COMBINATION PRODUCT CATEGORIES, FY 2005 (NUMBERS AND TYPES OF COMBINATION PRODUCTS) 58
NANOTECH COMBINATION PRODUCTS 59
OVERVIEW 59
NATIONAL NANOTECHNOLOGY INITIATIVE (NNI) 59
NANOTECH REGULATORY ENVIRONMENT 60
Nanotech Regulatory Environment (Continued) 61
COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH 62
Nanodiamond Drug Devices for Cancer Treatment 63
Nanotechnology-Magnetism Combination in Tiny Implantable Device for Drug Delivery 64
Implants Using Conducting Polymer Nanotubes 65
Calcium Phosphate Nanoparticles for Drug Delivery 66
Nano-scale Delivery Optimizes Chemotherapy Regimes 67
Drug Infused Nanoparticles 68
Drug Infused Nanoparticles (Continued) 69
Encapsulation of Drug Treatments in Nanoparticles 70
Silicon Nanowires for Drug Delivery 70
Minute Antibacterial Particles Destroy Drug-Resistant Germs 71
Biodegradable Cationic Core-Shell Nanoparticles for Co-delivery of Drugs and Genes 72
Stimuli-Sensitive Core-Shell Nanoparticles for Cancer Therapy 72
Polymer-Based Non-Viral Gene Carriers 73
POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY 73
Potential Health Effects: … (Continued) 74
TABLE 20 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATIONS, THROUGH 2014 $ MILLIONS 75
Chapter-5: CARDIOVASCULAR THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM024B)
INTRODUCTION 76
STUDY GOALS AND OBJECTIVES 76
REASONS FOR DOING THE STUDY 76
SCOPE OF REPORT 77
INTENDED AUDIENCE 78
METHODOLOGY AND INFORMATION SOURCES 79
RELATED BCC REPORTS 79
BCC ONLINE SERVICES 79
DISCLAIMER 80
SUMMARY 80
TABLE 21 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 80
FIGURE 5 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, 2007-2015 ($ MILLIONS) 81
OVERVIEW 82
CURRENT STATE OF CARDIOVASCULAR DISEASE 82
FIGURE 6 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006 (DEATHS PER 100,000) 83
ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE 84
Statins 84
Angiotensin Receptor Blocker 85
Angiotensin Converting Enzyme (ACE) inhibitors 85
EMERGING DRUG CLASSES 86
P2Y12 Inhibitors and Antagonists 86
Factor Xa Inhibitors 86
Cholesterol-Ester Transfer Protein (CETP) Inhibitor 87
TABLE 22 CETP INHIBITORS IN ACTIVE DEVELOPMENT 87
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET 87
Plavix Metabolizer 2C19 Triggers U.S. Warning 87
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION 88
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 89
TABLE 23 RECENTLY APPROVED DRUGS 89
TABLE 24 SUMMARY PIPELINE FORECAST 90
INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS 90
INDUSTRY STRUCTURE 90
TABLE 25 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 ($ MILLIONS) 91
MARKET CONCENTRATION AND PRICE SENSITIVITY 92
TABLE 26 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS) 93
MARKET TRENDS 94
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume 94
MASSIVE PATENT EXPIRATION IS A GROWTH OPPORTUNITY FOR GENERICS 94
TABLE 27 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($ MILLIONS) 95
MARKET EXPANSION VIA DISEASE PREVENTION IS THE FUTURE OF CARDIO CARE 95
ATRIAL FIBRILLATION IS A LARGE AND EMERGING DISEASE STATE 96
COMBINATION THERAPIES ARE SYNERGISTIC REVENUE GENERATORS 97
COMBINATION THERAPIES ARE …(CONTINUED) 98
Chapter-6: ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS (PHM062A)
INTRODUCTION 99
STUDY GOALS AND OBJECTIVES 99
REASONS FOR DOING THIS STUDY 99
SCOPE OF REPORT 99
INTENDED AUDIENCE 100
METHODOLOGY 100
INFORMATION SOURCES 100
ANALYST CREDENTIALS 100
RELATED BCC REPORTS 100
SUMMARY 101
TABLE 28 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 101
FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-2014 ($ MILLIONS) 101
FORECAST SUMMARY 102
OVERVIEW 103
DEFINITION AND MARKET STRUCTURE 103
What Is Alzheimer's Disease? 103
TABLE 29 U.S. ALZHEIMER'S PATIENTS, 2000–2050 (MILLIONS) 103
FIGURE 8 U.S. ALZHEIMER'S PATIENTS, 2000–2050 (MILLIONS) 104
Role of the Cholinergic System 104
Role of Beta-Amyloid Protein 105
Behavioral Manifestations of AD 106
Incidence and Prevalence 106
TABLE 30 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009–2050 (MILLIONS) 106
TABLE 31 PERCENT POPULATION OVER 65, BY REGION (%) 107
TABLE 32 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 107
FIGURE 9 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 107
TABLE 33 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET 108
FIGURE 10 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET (%) 108
TABLE 34 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 108
STAGES OF ALZHEIMER'S DISEASE 109
Stages of Alzheimer's … (Continued) 109
Stages of Alzheimer's … (Continued) 109
DIAGNOSIS 111
TABLE 35 DIAGNOSTIC TESTS 112
How Accurate are the Screening Tests? 112
How Accurate are the … (Continued) 113
KEY EVENTS 114
PATENT EXPIRATIONS 114
NEW PRODUCT LAUNCHES 114
PRICING 115
KEY MARKETS 115
TABLE 36 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, THROUGH 2014 ($ MILLIONS) 115
FIGURE 11 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2008-2014 ($ MILLIONS) 116
MARKET SIZE AND KEY PLAYERS 116
Chapter-7: ANTIPSYCHOTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM063A)
INTRODUCTION 117
STUDY GOALS AND OBJECTIVES 117
REASONS FOR DOING THIS STUDY 118
INTENDED AUDIENCE 118
SCOPE OF REPORT 119
METHODOLOGY 119
INFORMATION SOURCES 120
AUTHOR'S CREDENTIALS 120
RELATED BCC WORK CREDENTIALS 120
SUMMARY 120
TABLE 37 THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, THROUGH 2014 ($, MILLIONS) 121
FIGURE 12 THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, 2010–2014 ($, MILLIONS) 122
OVERVIEW 122
DEFINITION OF AN ANTIPSYCHOTIC DRUG 122
HISTORY OF ANTIPSYCHOTIC DRUGS 123
History of Antipsychotic Drugs 124
TYPES OF ANTIPSYCHOTICS ON THE MARKET 125
TYPICAL ANTIPSYCHOTICS 125
TABLE 38 CLASSES OF TYPICAL ANTIPSYCHOTICS ON THE MARKET AND THEIR SIDE EFFECTS 126
ATYPICAL ANTIPSYCHOTICS 127
TABLE 39 CURRENTLY APPROVED ATYPICAL ANTIPSYCHOTICS ON THE MARKET 128
TABLE 39 (CONTINUED) 129
TABLE 40 FEATURES OF TYPICAL VERSUS ATYPICAL ANTIPSYCHOTICS 130
TABLE 41 COST OF SELECTED ATYPICAL AND TYPICAL ANTIPSYCHOTIC DRUGS ($) 130
TABLE 41 (CONTINUED) 131
RECEPTOR TARGETS OF ANTIPSYCHOTIC DRUGS 131
DOPAMINE 131
SEROTONIN 132
GLUTAMATE 133
TACHYKININ 134
GLUCOCORTICOID 135
SIDE EFFECTS OF ANTIPSYCHOTICS 135
NEUROLOGIC SIDE EFFECTS (EXTRAPYRAMIDAL SYMPTOMS) 135
ANTICHOLINERGIC SIDE EFFECTS 136
CARDIOVASCULAR SIDE EFFECTS 137
METABOLIC SIDE EFFECTS 138
OTHER SIDE EFFECTS 138
TABLE 42 COMPARISON OF SIDE EFFECT PROFILES OF ANTIPSYCHOTICS ON THE MARKET 139
ANTIPSYCHOTICS IN CLINICAL DEVELOPMENT 139
TABLE 43 ANTIPSYCHOTICS IN CLINICAL TRIALS, ORDERED BY PHASE 140
TABLE 43 (CONTINUED) 141
TABLE 44 NUMBER OF ANTIPSYCHOTICS IN CLINICAL TRIALS, BY PHASE (NUMBER/%) 141
FIGURE 13 ANTIPSYCHOTICS IN CLINICAL TRIALS BY PRIMARY RECEPTOR TARGET 142
TABLE 45 COMPANIES WITH MORE THAN ONE ANTIPSYCHOTICS IN CLINICAL TRIALS OR ON THE MARKET* 143
Chapter-8: UBIQUITIN PROTEOSOME DRUGS: CANCER AND NEURODEGENERATIVE DISORDER
INTRODUCTION 144
STUDY GOALS AND OBJECTIVES 144
REASONS FOR DOING THIS STUDY 144
SCOPE OF REPORT 144
METHODOLOGY AND INFORMATION SOURCES 145
INTENDED AUDIENCE 145
ANALYST CREDENTIALS 145
RELATED BCC REPORTS 146
SUMMARY 146
TABLE 46 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 ($ MILLIONS) 147
FIGURE 14 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 ($ MILLIONS) 148
FIGURE 15 GLOBAL MARKET SHARES OF MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANIES, 2009 (%) 148
FIGURE 15 (CONTINUED) 149
OVERVIEW OF SCIENTIFIC BACKGROUND, AND SIGNIFICANCE OF UPS RESEARCH 149
UBIQUITINATION PHENOMENA AND ITS MAJOR COMPONENTS 149
Enzymatic Components as Possible Drug Targets 149
TABLE 47 ENZYMATIC COMPONENTS OF UBIQTUINATION/ DEUBIQUITINATION REACTION 150
FIGURE 16 ENZYMATIC STEPS IN UBIQUITINATION REACTION 150
FIGURE 17 HIERARCHICAL STRUCTURE OF UPS 151
Chain Topology as a Signaling Pathway 151
PROTEASOME MACHINERY 152
STRUCTURE AND FUNCTION 152
PROTEASOME AS A TARGET FOR DRUG DISCOVERY 153
UBIQUITIN-LIKE MODIFIERS (UBLS) 153
TABLE 48 UBLS, THEIR FUNCTION AND ASSOCIATED PATHOLOGY WITH THEIR DYSFUNCTION 154
MAJOR DRUG DEVELOPMENT AND PRODUCTS IN THE UPS RESEARCH FIELD 155
INDUSTRY OVERVIEW 155
Proteasome as a Drug Discovery 155
Velcade: The First UPS Product 155
Chemical Structure of Velcade and Its Mechanism of Action 156
FIGURE 18 CHEMICAL STRUCTURE OF BORTEZOMIB 156
Pharmacodynamics, Administration, and Side Effects 156
Velcade Sales Market 157
Overview 157
TABLE 49 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2009 (NUMBER) 157
MM Symptoms and Treatment 158
General Treatment for MM Today 158
TABLE 50 PROJECTED SIZE OF THE WORLDWIDE MM DRUG MARKET, 2009 AND 2018 ($ BILLIONS) 159
NHL and Mantle Cell Lymphoma 159
· Treatments for Mantle Cell Lymphoma and Other NHL 159
· CHOP Therapy 159
· MabThera/Rituxan 159
Current Major Market Participants in MM Treatment and Sales Forecast 160
Millennium Pharmaceuticals (a Subsidiary of Takeda) 160
TABLE 51 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 ($ MILLIONS) 160
FIGURE 19 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 ($ MILLIONS) 161
Celgene 161
· Revlimid 161
· Thalomid 162
TABLE 52 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, THROUGH 2016 ($ MILLIONS) 162
FIGURE 20 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, 2006-2016 ($ MILLIONS) 163
Market Shares of Millennium/Takeda, Celgene, and Other Companies' Drugs 163
TABLE 53 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO THOSE PROJECTED IN 2011* (%) 164
FIGURE 21 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO PROJECTED SHARES IN 2011* (%) 164
FIGURE 21 (CONTINUED) 165
Millennium Pharmaceuticals/Takeda's New Developments 165
TABLE 54 EXAMPLE OF COSTS OF SIDE EFFECTS OF CHEMOTHERAPY TREATMENT PER PATIENT IN THE U.S., 2006 ($ THOUSANDS) 166
New Formulations for Velcade and Second-Generation Inhibitors 166
Improvement of Velcade 166
Second-Generation Inhibitor MLN9708 166
TABLE 55 CURRENT R&D ACTIVITY IN UPS BY MILLENNIUM/TAKEDA 167
Velcade in Combination with Other Treatments 167
COMPANIES WORKING ON SECOND-GENERATION PROTEASOME INHIBITORS 167
OVERVIEW 167
Current Market Participants 167
TABLE 56 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET 168
Millennium Pharmaceuticals (a Subsidiary of Takeda) 168
Onyx Pharmaceuticals/Proteolix 168
· Carfilzomib 168
· ONX 0912 169
· ONX 0914 (PR-957) 169
TABLE 57 WORLDWIDE MARKET FOR AUTOIMMUNE DISORDERS: LUPUS, RA, AND IBD, 2008 ($ BILLIONS) 170
Cephalon 170
• CEP-18770 170
Nereus Pharmaceuticals 170
• Salinosporamide (NPI-0052) 170
Salinosporamide … (Continued) 171
Chapter-9: ONCOLOGY ADJUVANTS: TECHNOLOGIES AND GLOBAL MARKETS (PHM067A)
INTRODUCTION 172
STUDY GOALS AND OBJECTIVES 172
REASONS FOR DOING THIS STUDY 172
INTENDED AUDIENCE 173
SCOPE OF REPORT 173
METHODOLOGY 173
INFORMATION SOURCES 174
ANALYST CREDENTIALS 174
RELATED BCC REPORTS 174
SUMMARY 174
TABLE 58 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS, THROUGH 2015 ($ MILLIONS) 175
FIGURE 22 GLOBAL ONCOLOGY ADJUVANT SALES BY MARKET GEOGRAPHY, 2009 AND 2015 (%) 176
OVERVIEW 177
HISTORY AND CURRENT STATE OF ONCOLOGY AND CONCEPTS OF ADJUVANTS IN ONCOLOGY 177
TYPES OF CANCER 178
DEFINITION OF THE INDUSTRY 179
IMPORTANCE OF THE INDUSTRY 180
PRODUCT LIFE CYCLES 180
TABLE 59 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG 181
DEVELOPMENT OF ONCOLOGY ADJUVANTS 181
TABLE 60 HISTORICAL PIPELINE OF FDA-APPROVED ONCOLOGY ADJUVANTS 182
HUMAN CLINICAL DEVELOPMENT 183
NEW DRUG ACTIVITY 183
FUTURE DEVELOPMENTS 184
2008 TO 2009 DRUG ACTIVITY 184
2008 to 2009 Drug Activity (Continued) 185
WITH AN EYE TOWARD THE FUTURE 186
TYPE OF APPLICATIONS IN THE HUMAN ONCOLOGY ADJUVANT MARKETPLACE: CHEMOTHERAPY, IMMUNOTHERAPY, AND RADIOTHERAPY 186
TABLE 61 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS SALES BY PRODUCT TYPE, THROUGH 2015 ($ MILLIONS) 187
FIGURE 23 ONCOLOGY ADJUVANTS SALES: BY ADJUNCTIVE PRODUCT TYPE, 2008-2015 ($ MILLIONS) 188
HUMAN CANCERS 188
TABLE 62 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS BY CANCER INDICATION, THROUGH 2015 ($ MILLIONS) 189
FIGURE 24 ONCOLOGY ADJUVANTS FORECAST SALES: BY TYPE OF CANCER 2008-2015 ($ MILLIONS) 189
RISK FACTORS FOR DEVELOPING CANCERS 190
TABLE 63 RISK FACTORS ASSOCIATED WITH HUMAN CANCERS 190
TABLE 63 (CONTINUED) 191
TABLE 64 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN MEN 192
TABLE 65 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN WOMEN 192
TABLE 66 HUMAN CANCER TRENDS, ESTIMATED, 2008-2015 (NUMBER OF CASES) 193
BREAST 193
TABLE 67 GLOBAL SALES FORECAST OF BREAST CANCER ONCOLOGY ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 194
RECTUM AND COLON 194
TABLE 68 GLOBAL SALES FORECAST OF COLORECTAL CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 195
NON-HODGKIN LYMPHOMAS 195
TABLE 69 GLOBAL SALES FORECAST OF LYMPHOMAS ADJUVANTS BY GEORGRAPHY, THROUGH 2015 ($ MILLIONS) 196
LUNG 196
TABLE 70 GLOBAL SALES FORECAST OF LUNG CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 197
LEUKEMIA 197
TABLE 71 GLOBAL SALES FORECAST OF LEUKEMIA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 198
PROSTATE CANCER 198
TABLE 72 GLOBAL SALES FORECAST OF PROSTATE CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 198
GLIOBLASTOMA 199
TABLE 73 GLOBAL SALES FORECAST OF GLIOBLASTOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 199
MULTIPLE MYELOMA 199
TABLE 74 GLOBAL SALES FORECAST OF MULTIPLE MYELOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 200
To order this report:
Pharmaceutical Industry: 2010 Pharmaceuticals Research Review
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg: [email protected] |
|
US: (805)-652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article